Provided by Tiger Trade Technology Pte. Ltd.

CG Oncology Inc.

78.23
-1.5800-1.98%
Post-market: 78.230.00000.00%16:10 EDT
Volume:947.53K
Turnover:74.35M
Market Cap:6.93B
PE:-28.72
High:79.89
Open:79.44
Low:77.51
Close:79.81
52wk High:80.97
52wk Low:25.25
Shares:88.64M
Float Shares:64.73M
Volume Ratio:1.27
T/O Rate:1.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.7235
EPS(LYR):-2.0826
ROE:-26.41%
ROA:-17.67%
PB:6.74
PE(LYR):-37.56

Loading ...

CG Oncology Inc - No Grade 3 or Higher Treatment-Related Adverse Events or Deaths Reported

THOMSON REUTERS
·
May 15

CG Oncology Inc - High-Grade Event-Free Survival 96.0% at 3 Months, 89.5% at 6 Months in ITT Population

THOMSON REUTERS
·
May 15

CG Oncology Inc - Efficacy Comparable Across Treatment Arms and Bcg-Exposed or Bcg-Unresponsive Populations

THOMSON REUTERS
·
May 15

CG Oncology Reports Positive First Results From Core‑008 Cohort Cx Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk Bcg-Exposed and Bcg-Unresponsive Patients

THOMSON REUTERS
·
May 15

CG Oncology Price Target Raised to $82.00/Share From $77.00 by Truist Securities

Dow Jones
·
May 14

CG Oncology, Inc. (CGON) Gets a Buy from Truist Financial

TIPRANKS
·
May 14

CG Oncology Inc : Truist Securities Raises Target Price to $82 From $77

THOMSON REUTERS
·
May 14

U.S. RESEARCH ROUNDUP- Cisco, DTE Energy, Marvell Technology

Reuters
·
May 14

CG Oncology to present Phase 2 trial results for cretostimogene-gemcitabine combo in NMIBC

Reuters
·
May 12

CG Oncology’s Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC

GlobeNewswire
·
May 12

CG Oncology price target raised to $80 from $77 at Wedbush

TIPRANKS
·
May 12

CG Oncology Analysts Boost Their Forecasts Following Q1 Earnings

Benzinga Earnings
·
May 12

CG Oncology's BLA Completion Target for Creto in Q4 to Comfort Investors, RBC Says

MT Newswires Live
·
May 12

CG Oncology Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 11

CG Oncology Is Maintained at Outperform by Wedbush

Dow Jones
·
May 11

CG Oncology, Inc. (CGON) Receives a Rating Update from a Top Analyst

TIPRANKS
·
May 11

RBC Capital Remains a Buy on CG Oncology, Inc. (CGON)

TIPRANKS
·
May 11

CG Oncology Earns Buy Rating as Analyst Sees High Phase III Success Odds and Strengthened BLA Timeline for Lead Asset Creto

TIPRANKS
·
May 11

Truist Financial Sticks to Its Buy Rating for CG Oncology, Inc. (CGON)

TIPRANKS
·
May 11

RBC Capital Adjusts CG Oncology PT to $81 From $79, Maintains Outperform Speculative Risk Rating

MT Newswires Live
·
May 11